Brokerages Set Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Target Price at $21.00

Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) have earned an average rating of “Buy” from the eight analysts that are covering the firm, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $21.00.

Several equities research analysts recently issued reports on ZVRA shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Zevra Therapeutics in a research note on Friday, October 11th. Canaccord Genuity Group decreased their price target on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating for the company in a report on Thursday, November 14th. Roth Mkm upped their price objective on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the company a “buy” rating in a research note on Tuesday, September 24th. JMP Securities assumed coverage on shares of Zevra Therapeutics in a research note on Tuesday, September 24th. They set an “outperform” rating and a $17.00 target price for the company. Finally, Maxim Group upped their price target on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the stock a “buy” rating in a research note on Tuesday, September 24th.

Zevra Therapeutics Stock Performance

Zevra Therapeutics stock opened at $8.76 on Friday. Zevra Therapeutics has a fifty-two week low of $4.20 and a fifty-two week high of $9.76. The firm’s 50 day simple moving average is $8.75 and its 200-day simple moving average is $7.45. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88. The company has a market cap of $467.57 million, a P/E ratio of -4.45 and a beta of 1.97.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.25). The firm had revenue of $3.70 million for the quarter, compared to analysts’ expectations of $5.04 million. Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. During the same quarter in the previous year, the firm posted ($0.40) earnings per share. As a group, equities research analysts predict that Zevra Therapeutics will post -1.96 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Vestal Point Capital LP acquired a new position in Zevra Therapeutics during the third quarter worth $3,644,000. Sanctuary Advisors LLC bought a new stake in shares of Zevra Therapeutics during the 2nd quarter worth about $474,000. Propel Bio Management LLC acquired a new position in shares of Zevra Therapeutics during the 3rd quarter valued at about $1,248,000. Simplify Asset Management Inc. bought a new position in shares of Zevra Therapeutics in the 3rd quarter valued at approximately $833,000. Finally, FMR LLC lifted its holdings in Zevra Therapeutics by 282,687.5% in the 3rd quarter. FMR LLC now owns 2,313,202 shares of the company’s stock worth $16,054,000 after purchasing an additional 2,312,384 shares during the last quarter. Institutional investors own 35.03% of the company’s stock.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.